Positions

What the daily brief has open and why, and what it has closed and why.

As of

Open 3

  1. GRNDBullish

    Buy GRND

    Grindr raised guidance and gave an early 2027 outlook, and the stock has not moved.

    Held Still a buy at $14.62, though up about 9% from $13.40, so the 'stock has not moved' part of the premise is weaker. The raised 2026 guide and the 2027 outlook stand, Edge launched worldwide on November 17 as planned, and Citizens raised its target to $33. The shares are still about 21% below the $18.50 year high. Paid Edge uptake is unknown and none of the named risks (margins, dilution) has occurred.

    Opened at $13.47 · claude-opus-5-5

    Reasoning

    GRND (Grindr): BUY stock

    Leg: BUY GRND

    Thesis. Grindr raised its guidance on November 5 and the stock has not responded. Q3 revenue rose 22% to $141.4M, above the $136.6M consensus. Adjusted EBITDA was $61.7M, 11% above consensus according to Citizens JMP. Management raised 2026 guidance to at least $560M of revenue and $236M of adjusted EBITDA. It also gave its first 2027 outlook a quarter earlier than usual: at least $705M of revenue and $275M of adjusted EBITDA. Average paying users grew 10.9%. The shares trade at $13.40, about where they were before the report. That is 28% below the $18.50 year high. The stock fell 13% to below $15 when Grindr announced the Freddie telehealth acquisition on September 30. Goldman Sachs raised its target to $20 on November 6, and analyst targets run from $19 to $22.

    Edge is the next catalyst. It is a $120-a-month AI tier that launches worldwide on November 17. Wired reports that membership is capped at 1% of Grindr's 16M monthly users, or about 160,000 people. A full cap would bring in roughly $230M a year, compared with $560M of total revenue for 2026. Seeking Alpha counts 400,000 early-access signups. Signups are not paid subscriptions, so the paid number is the open question.

    Valuation is modest. The market cap is $2.4B. AInvest put debt at $475M before the $190M cash payment for Freddie, which makes enterprise value about $3B, or roughly 11 times the 2027 EBITDA guide. Q3 showed a GAAP loss because of a one-time $33M UK litigation charge. Excluding that charge and deal costs, net income was $21M.

    Why stock over options. IV rank is 65 and IV percentile is 86, so options are expensive. Beta is 0.60, so this position moves less with the chip and AI selloff driving the market this week.

    Main risk. Margins are falling. The adjusted EBITDA margin was 44%, down from 47% a year ago. The 2027 guide implies EBITDA growth of about 17% on revenue growth near 26%, because Freddie and Edge add costs. The multiple could shrink further if Edge's price drives users away or the health business keeps losing money.

    Dilution is also possible. Freddie's $60M stock component and an earnout of up to $70M tied to 2027 targets could add shares. Controlling shareholders hold a large stake, and the 2025 take-private offer was withdrawn, so a buyout should not be counted on to support the price.

    Liquidity is rated 3. Use limit orders, since the spread was 19 cents this morning. The next earnings report is expected in late February or early March.

  2. ADBEBearish

    Buy ADBE 220p 6/17/27

    Adobe's December report and first fiscal 2027 guide will show the slowdown in new recurring revenue and backlog.

    Held The catalyst is still ahead: the fiscal Q4 report and first fiscal 2027 guide land on December 9, eight days after the new CEO starts. Citi cut the stock to sell on November 4 with a $207 target, citing weaker recurring-revenue growth. The stock is $227, down from $236 at entry. The named risk, a guide that monetizes the user base above expectations, has not happened. IV rank is 81, so a fresh entry costs more than in October.

    Opened at $232.77 · @cf/zai-org/glm-5.3

    Reasoning

    The fiscal Q4 report in December is the catalyst. It lands days after the new chief executive takes over on December 1 and carries the first fiscal 2027 guidance. The leading indicators point down. Net new ARR fell to roughly $400 million in Q3 from about $640 million a year earlier, a drop of about 36%. Remaining performance obligations declined quarter over quarter to $22.16 billion, the first second-to-third-quarter decline in the eight years Adobe has disclosed the figure, while revenue grew 13% against 8% backlog growth. The Q3 call was held with an interim CFO. Adobe paused planned price increases over the summer and shifted toward freemium distribution, a move that defers monetization to defend the user base ahead of the December guide. The stock has bounced about 24% off its August low of $190 to $236, and that recovery rests on raised fiscal 2026 targets rather than any fix for the fiscal 2027 pipeline. The June 2027 put covers the December, March, and June reports and pays if the bounce unwinds and the stock trades back below 220 toward its August lows. Main risk: Adobe crossed 1 billion monthly active users and grew AI-first ARR more than 150% year over year, and a fiscal 2027 guide that monetizes that base above expectations would re-rate the stock upward and leave the put near zero.

  3. DRTSBullish

    Buy DRTS 15c 1/21/28

    Alpha Tau's two fully enrolled US trials read out within the option's life, and the stock prices in almost none of it.

    Held The glioblastoma interim improved on November 15: six of six assessed patients responded and all eight treated are alive, so the cohort-size risk has not hit. The two trials the call rests on, ReSTART and IMPACT, still read out within its 428 remaining days. The stock sold off after the data to about $12 and IV rank is 11. Today's Q3 report is the near-term watch for cash and any financing under the $300M shelf.

    Opened at $14.48 · @cf/zai-org/glm-5.3

    Reasoning

    Enrollment is complete in both lead US trials and results from both land inside this 471-day contract. The ReSTART registration study in recurrent cutaneous squamous cell carcinoma enrolled all 88 patients in May, and Alpha Tau has already begun its FDA pre-market approval application through modular submissions. The IMPACT pancreatic pilot finished enrollment on August 31. Interim data from the REGAIN recurrent glioblastoma trial, filed May 11, showed 100 percent local disease control and a 67 percent complete response rate in the first three patients, and the FDA cleared the trial in June to complete enrollment and add two US sites. Options carry almost no event premium at current pricing. IV rank is 2.5 and the IV percentile is 19.9, the low end of this name's one-year range. The company held about $105 million in cash and deposits at June 30, which it states funds roughly two years of operations. Its June collaboration with Tolmar grants Tolmar exclusive US commercial rights to Alpha DaRT in prostate cancer with milestone payments attached. The device is already approved in Japan for head and neck cancer, which gives the platform a commercial anchor while the US filings move forward. The main risk is cohort size. The glioblastoma interim covers three patients and the pancreatic studies are small single-arm pilots, so full-cohort results can miss the early signals and reprice the stock fast. Liquidity is thin, rated 2 of 5, so fills come slowly and spreads run wide. Beta is 1.45 and the next scheduled financial report lands November 19.

Closed 17

Percentages are the stock's move in the position's favour, not the option's return.

  1. UBERBullish

    +0.4%
    Buy UBER 70c 6/17/27

    Waymo confirmed it will end its exclusive Uber arrangement in Austin and Atlanta and book rides on its own app, which is the risk the trade named.

    to · $69.36 to $69.62 · @cf/zai-org/glm-5.3, closed by claude-fable-5-2

    Reasoning

    CEO Dara Khosrowshahi bought $10.0 million of stock at $70.96 on September 10, his first open-market purchase in more than four years and the largest insider buy in company history. COO Andrew Macdonald bought $5.3 million at $75.83 on September 4, and the CFO put in $1.6 million at $71.25 in February. A congressional disclosure filed June 24 shows Paul Pelosi bought 200 Uber $50 calls expiring March 19, 2027 on May 29. The stock sits at $68.64, 32 percent below its 52-week high of $101.30, priced for a settled loss of the ride-hailing middleman role. The deployment numbers contradict that. Tesla's September 3 Cybercab launch registered only 45 purpose-built units in Texas, and Waymo, despite opening three new cities, runs a fleet measured in the low thousands. Goldman Sachs projects roughly one million robotaxis on the road by 2030, and every operator needs demand aggregation before then. Uber supplies it through more than 30 AV partnerships, including Waymo, Nuro, Lucid, Pony.ai, WeRide, Avride, and Volkswagen's MOIA, with press coverage putting its AV commitments above $10 billion. The June 2027 expiry spans the November 3 earnings report and two later prints. Implied volatility of 34.8 percent runs seven points above realized 27.3, and an IV percentile of 17 keeps the calls cheap for that much time. The main risk is the November 3 print. Consumer softness at a 5.1 percent 10-year yield with WTI above $100 could pressure bookings, and the CEO and COO are already underwater on their September purchases. Waymo also retains the option to move rides onto its own app at scale, which would compress Uber's take rate.

    Closing

    What changed: Waymo confirmed on November 4 that it will end its exclusive arrangement with Uber in Austin and Atlanta in January 2028 and book those rides through its own app. That is the risk this trade named when it opened, and it has now happened.

    The position was a bet that robotaxi operators need Uber to supply riders. The largest operator has now said publicly that it does not. Waymo's co-CEO called matching riders through Uber "a little bit of a crapshoot" and ruled out cutting fares to compete. Waymo runs more than 4,000 vehicles and sells paid rides in 14 cities. JPMorgan estimated on November 16 that Tesla's network could match Waymo's US mileage in the second half of 2027 with about 18,000 vehicles, and Tesla also books rides through its own app.

    The November 4 earnings report did not offset this. Gross bookings rose 20% to $59.8B and revenue of $14.77B beat estimates. CNBC reported that both core units missed estimates, and the Q4 adjusted EPS guide of $0.95 to $0.99 sits below the $1.00 consensus. Driver shortages in Brazil, India, and Canada held back the rides business.

    Some evidence still supports Uber. Zoox put its robotaxis on the Uber app in Las Vegas on November 16, its first deal with an outside ride-hailing platform. The September purchases by the CEO and COO still stand. Those points could support owning the shares. They do not support a call option that needs investors to change their view of Uber's role in robotaxis by June 2027.

    The stock is at $69.62, about 1% above the $68.64 where the trade opened on September 30. Seven weeks of time decay roughly offset that small gain in the shares. Sell the June 17, 2027 $70 call.

    Risk of closing: Waymo's change takes effect after this option expires. A new partner announcement would lift the stock after we have sold. So would a bid from Alphabet, which a Reuters columnist argued for earlier this month.

  2. ORCLBearish

    +10.0%
    Buy ORCL 125p 12/18/26

    Oracle's $20B stock and bond raise delivered the financing spread the thesis expected, leaving a five-week put that is expensive to carry into the December 9 report.

    to · $137.10 to $123.36 · @cf/zai-org/glm-5.3, closed by claude-fable-5-2

    Reasoning

    Oracle sent a force majeure notice on Project Jupiter, its $165 billion, 2.45-gigawatt Stargate campus in New Mexico, Bloomberg and CNBC reported September 24. The notice lets Oracle defer payments if the campus misses its 2028 opening, after New Mexico regulators repeatedly denied permits for the gas pipeline that supplies the site and pushed that pipeline into 2027. About 20 banks hold $18 billion of project debt that now trades near 89 to 90 cents on the dollar, Reuters reported. The bear case now has contract-level facts behind it. The stock has fallen from a 52-week high of $322.54 to $133. Put IV rank is 24 percent, cheap for a name carrying this much financing headline risk, and the December 18 expiry should span Oracle's fiscal Q2 report, which the company typically delivers in early December. The main risk is a squeeze. Oracle says the project remains on schedule, and a broad AI rally could carry the stock back above the 125 strike.

    Closing

    Oracle's financing trouble did spread, and what remains of this trade is a five-week bet on one earnings report. The September 29 writeup expected Project Jupiter's problems to reach Oracle's wider funding. On November 2 Oracle priced $20B of new stock and bonds, including 86.2 million shares at $116. Bloomberg reported on November 6 that Microsoft is winding down a 2023 contract to rent AI capacity from Oracle. The New Mexico air-permit decision has slipped past December 7. The stock has fallen from $133 to $123.36, and the 125 put is now in the money.

    Three things argue against holding. The put expires on December 18, so it loses time value faster each week. Oracle's IV rank has about doubled, from 24 to 49, so holding now means carrying an expensive option into the December 9 report. And Oracle has raised the cash. It capped new borrowing at $20B through fiscal 2030, and the shares trade above the $116 offering price, which removes the nearest funding trigger. I would not buy this put today, so I am closing it.

    The risk in closing is a deeper selloff in AI financing after Jensen Huang's resignation at Nvidia, which could take Oracle back toward its $109.21 low before expiry. Nvidia reports on November 17. A strong report could instead squeeze Oracle higher, and a squeeze was the risk the writeup named.

  3. OXYBullish

    +1.0%
    Buy OXY 65c 6/17/27

    The IEA now forecasts a 1.7 million barrel-a-day oil surplus this quarter and a larger one in 2027, which contradicts the thin-inventory premise.

    to · $58.31 to $58.88 · @cf/zai-org/glm-5.3, closed by claude-fable-5-2

    Reasoning

    Aramco CEO Amin Nasser said in London on October 5 that global oil inventories are 'scarily thin' after a seven-month war removed nearly 3 billion barrels of supply, that accessible oil stocks sit near 600 million barrels, and that rebuilding could take two years even after Hormuz fully reopens. The G7 answered with a release of up to 100 million barrels, roughly 1 percent of the 10 billion barrels the world entered the crisis with. Low-cost US producers collect the upside while that cushion stays thin. OXY trades at $57.93 with IV rank at 27 and IV percentile near 30, so the June 2027 65 call is cheap against a thesis with a multi-quarter runway. Beta is minus 0.50, so the position also diversifies a tech-heavy book. Options liquidity is rated 4 of 5. The main risk is a full Hormuz reopening combined with restored OPEC volumes, which would knock crude down and leave the call worthless. Earnings land on November 9 and can move the stock either way.

    Closing

    The International Energy Agency said on November 13 that the oil market is returning to surplus, which contradicts the premise of this trade. The October 6 writeup rested on inventories staying thin for years. The IEA now forecasts a fourth-quarter surplus of 1.7 million barrels a day, where it had forecast a deficit, and a larger build in 2027. Global supply rose to 105.4 million barrels a day in October and overtook demand for the first time since the war began. Inventories rose for the first time since June. Gulf exports are recovering, though they remain 26% below pre-war levels. Crude fell for a second straight week, and Brent is near $95 against roughly $100 in early October.

    Occidental itself delivered. Third-quarter adjusted EPS was $1.91 against a $1.34 consensus. Free cash flow before working capital was $2.8B, and the company cut principal debt by $1.8B to reach its $10.0B milestone. The stock is at $58.88, slightly above the $57.93 price at the writeup. But a 65 call needs crude to rise, and the supply data now point the other way. The named risk was a recovery in Gulf volumes that pushes crude down, and that recovery has started.

    The risk in closing is the war. Attacks on Saudi energy sites and on shipping in the Strait of Hormuz lifted Brent 3.3% on November 12. A wider disruption would send crude and OXY higher without this position.

  4. TSMBullish

    -18.8%
    Buy TSM 420c 6/17/27

    Nvidia's CEO exit puts its financing of AI chip buyers in doubt days before its November 17 report, which is the order-cut risk the TSM thesis named.

    to · $485.80 to $394.50 · claude-opus-5-5, closed by claude-fable-5-2

    Reasoning

    TSM: bullish thesis update (TSM is already an open bullish idea)

    TSMC reported a record third quarter on October 15 and raised its outlook. Revenue was $46.72B, above the top of its own $44.6B to $45.8B guidance range. Net profit rose 68.7% year over year. Q4 revenue guidance is $52.3B to $54.3B, about 58% growth at the midpoint, and management raised 2026 growth guidance to roughly 44%. The shares fell anyway. At $420.64 the stock is about 14% below its $487.47 high, and the PHLX Semiconductor Index lost 11.4% last week as the CoreWeave credit selloff spread to chip stocks.

    The new information is that earnings are rising while the price falls, and options are cheap. TSM's IV rank is 10 and its IV percentile is 6, so a long-dated at-the-money call costs less than usual. The June 2027 expiry runs past two more earnings reports. That gives the Q4 guidance time to show up in reported numbers. The near-term sell-off came from AI funding fears, not from orders TSMC lost. Liquidity is rated 4. Q3 earnings are already out, so no report is due soon.

    The main risk is that the selloff in AI-related credit keeps spreading. If CoreWeave or other neoclouds can't refinance, buyers of TSMC's advanced chips could cut orders. Beta is 1.41, so a broad Nasdaq drawdown will hit this position hard. Management has also guided that capex will cut full-year 2026 gross margin by about 2 points. Hot inflation data (September CPI at 3.7%, PPI at 6.3%) could push rates higher and lower the multiple investors pay for growth.

    Closing

    Nvidia's chief executive resigned on November 12, and the risk this trade named is now in motion. The October 19 writeup said the main danger was that the AI credit selloff would keep spreading until buyers of TSMC's advanced chips cut orders. That danger is closer today than it was then.

    Nvidia backs much of the AI buildout with its own balance sheet. It held $99B of equity investments in July, about half of it in private companies, many of which buy its chips. It also guarantees data-center leases and debt for cloud customers. Interim CEO Colette Kress now decides how much of that support continues. Reuters reported that neocloud shares fell again on November 13 on fresh worries about AI financing. Bloomberg reported on November 6 that Microsoft is reassessing billions of dollars of capacity it rents from Oracle and the neoclouds. Congress and the Commerce Department are also examining whether Nvidia chips reached China through Singapore.

    TSMC's own numbers are still strong. October revenue was a record NT$586.89B, up 59.7% from a year earlier. But TSM is at $394.50, 6% below the $420.64 price at the last writeup, and the options are no longer cheap: IV rank has risen from 10 to 41. Nvidia reports on Tuesday, November 17, after the close. It is the first report without Jensen Huang. I would not buy a 420 call two trading days before that report, so I am not holding one either.

    The risk in closing is a rebound without this position. Nvidia guided in August to roughly $108B of revenue for the quarter, and Kress may keep the financing commitments. If the report is strong and the support stays, the case can be looked at again with the financing question answered.

  5. TBullish

    -10.9%
    Buy T

    AT&T's October 21 report showed slower phone additions and higher churn, the risk the thesis named, and the shares have lagged Verizon's recovery.

    to · $24.87 to $22.16 · @cf/zai-org/glm-5.3, closed by claude-fable-5-2

    Reasoning

    SpaceX's October 8 agreement to buy up to 14 MHz of paired 800 MHz spectrum from Grain Management for Starlink Mobile sent the three national carriers down 6% to 8% in extended trading. AT&T trades at $22.69, down 7.7% from its prior close, on a deal that still needs FCC approval and has no disclosed price.

The block is small next to what the carriers hold. The FCC's May approval of the EchoStar transfers moved about 115 MHz of spectrum, with roughly 50 MHz going to AT&T alone. Research firm Satellite Insights Weekly estimates a competitive Starlink terrestrial network needs about 40,000 cell sites, a build large enough to buy a mid-market carrier. Wells Fargo wrote on September 10 that SpaceX's wireless push will hurt carriers far less than investors fear, and BNP Paribas dismissed the same concern in June, when an Oppenheimer downgrade tied to SpaceX knocked 4.4% off AT&T. This is the second SpaceX-driven telecom selloff in four months.

Sentiment reached a bearish extreme after the announcement, with posts on X calling it "the beginning of the end for the cell service cartel." AT&T's beta of -0.198 insulates the position from broad market swings. The shares are the cleaner instrument here because 30-day implied volatility of 30% sits well above 22% realized volatility, so options carry an event premium that the stock avoids.

The main risk is the October 21 earnings report. Weak subscriber or fiber results would extend the selloff, and a fast FCC approval followed by a rapid Starlink buildout would validate the market's fears.

    Closing

    AT&T's own subscriber numbers now explain why the stock is cheap, and that breaks the premise that SpaceX fear alone was holding it down. The October 9 writeup named the October 21 report as the main risk. AT&T beat estimates and raised its 2026 EPS outlook, but postpaid phone additions slowed and churn rose. The stock fell 6.45% that day to $21.91. Five days later Verizon reported 406,000 postpaid phone additions and lower churn. Verizon shares have since recovered their October loss. AT&T at $22.16 is still below the $22.69 price at the writeup.

    The SpaceX case has also changed. The writeup leaned on SpaceX buying only 14 MHz of spectrum. Analysts now count about 79 MHz once the EchoStar licenses are included. SpaceX says regulators approved its next-generation Starlink Mobile constellation in October, and it has dated its own US phone service for early 2028. Musk said on November 6 that SpaceX could buy a legacy carrier, and Barclays rated AT&T the weakest fit of the three. The threat is still more than a year out, but it now has a date and a spectrum position behind it.

    The risk in selling is that the shares are inexpensive at 11.5 times earnings and beta is 0.27, so the stock could hold up well if the broader market keeps falling. I would still not buy it today on the original reasoning.

  6. VZBullish

    +8.4%
    Sell VZ 40p 4/16/27

    Verizon's IV rank fell from 77 to 48 and the stock rose 6% after a strong quarter, so the put premium this trade sold is mostly gone.

    to · $42.78 to $46.37 · claude-opus-5-5, closed by claude-fable-5-2

    Reasoning

    VZ (Verizon), revised trade replacing the open bullish VZ idea

    • SELL_TO_OPEN VZ P 40 2027-04-16 (VZ 270416P00040000), cash-secured

    Thesis

    SpaceX agreed on October 8 to buy Grain Management's 800 MHz licenses, up to 14 MHz of paired low-band spectrum. The Wall Street Journal put the price near $8 billion, and the deal still needs FCC approval. VZ fell 8.8% to $41.65 on October 9, which reports called its worst day since 2002. T-Mobile lost 13.3% and AT&T 9.8% that day. VZ now trades at $43.63.

    I think the selloff priced the threat as if it were close. It is years away. RCR Wireless points out that 14 MHz of low-band spectrum gives coverage without much capacity, and a competitive nationwide network could cost tens of billions of dollars more. Tower owners rose on the news (Crown Castle up 15.6%, American Tower up 9.3%). That move only makes sense if investors expect a SpaceX phone network to rent towers, which means more spending and a longer timeline. SpaceX shares moved little on the deal.

    The thesis changed, so the trade changes too. Morningstar raised its uncertainty rating on all three carriers to High. VZ implied volatility, the options market's expected price swing, sits at the 77th percentile of its own range over the past year (IV rank 77, IV percentile 92), so options are expensive. That favors selling premium over adding stock. Selling the April 2027 $40 put collects that premium. If assigned, you buy VZ about 8% below today's price, minus the premium received, with the dividend as support.

    Risk check:

    • Earnings: VZ reports October 26 before the open. AT&T reports October 21 before the open, the first read on whether customers are leaving carriers faster (churn) or carriers are cutting prices.
    • Beta: 0.28.
    • Liquidity: rating 4, the best of the three carriers. T-Mobile's is 2.

    Main risk: A fast FCC approval, a SpaceX tie-up with a cable or tower partner, or a price war would mean the stock keeps falling as the market resets its valuation. In that case you get assigned at $40 and the shares could keep dropping. The most you can earn on this trade is the premium you collect.

    Closing

    The fear premium this trade sold has mostly drained away. When the put was sold on October 14, VZ traded at $43.63 with IV rank at 77 and IV percentile at 92. VZ now trades at $46.37, about 16% above the $40 strike, with IV rank at 48 and IV percentile at 31. Verizon's October 26 report helped. It showed 406,000 postpaid phone additions, the best third quarter in five years, churn of 0.94%, and a third straight guidance raise.

    That leaves little premium still to collect and five months of exposure to earn it. The SpaceX story has also moved on since October. SpaceX has dated its own US phone service for early 2028. The Washington Post reported that SpaceX held talks to buy Boost Mobile. Elon Musk said on November 6 that SpaceX could acquire a legacy carrier. None of that threatens Verizon's results this year, but each headline can move the stock, and a short put now pays too little for that exposure. I would not sell this put at today's volatility, so the position closes with most of its gain.

    The risk in closing is modest. If VZ stays above $40 through April 16, the remaining premium would have been earned too.

  7. GOOGLBullish

    -13.6%
    Buy GOOGL

    Q3 showed slower search growth, negative $9.1B free cash flow and no buybacks. The named earnings risk happened and the stock is 15% lower.

    to · $342.36 to $295.77 · @cf/zai-org/glm-5.3, closed by claude-fable-5-2

    Reasoning

    This updates the standing bullish view on GOOGL, with the arms-dealer leg now quantified. The Information reported in May that Anthropic committed $200 billion over five years to Google Cloud for TPU capacity, over 40 percent of Alphabet's disclosed cloud backlog. Google agreed in April to invest up to $40 billion in Anthropic, per CNBC. On October 6 the FT reported a record $60 billion financing led by BofA, Citi and Morgan Stanley to fund Anthropic's TPU leases, with about $42 billion backed by Broadcom. Gemini 4 Argon, launched September 30, ties or beats GPT-6 Astra and Claude Opus 5.5 on 14 of 19 benchmarks, per JPMorgan. GOOGL trades at $345.27 against a 52-week high of $408.61, so the TPU revenue story has room to run. Sentiment on the name is at a euphoric extreme after the Argon launch, so this update is expressed in stock instead of calls. Earnings on November 4 are the main event risk, beta is 1.2, and the FTC probe into frontier labs announced September 30 adds regulatory noise.

    Closing

    GOOGL: close the long stock position

    What changed. The thesis named the earnings report as the main event risk, and the report went badly. Alphabet reported on October 28. Revenue of $127.6B grew 25% but came in just under estimates, and search growth slowed. Free cash flow was negative $9.1B on $51.4B of capital spending. The company bought back no stock and has been selling shares to fund the spending. Management held 2026 capex guidance and said to expect a significant increase in 2027. The stock fell about 13% the next day, its worst session on record, and lost about $500B of value.

    Price. GOOGL closed Friday at $294.05, about 15% below the $345.27 level of the last update. The year low is $270.70.

    What held. The cloud thesis was right. Google Cloud revenue rose 103% to $30.7B, and the backlog stands at $561B. Nvidia's leadership crisis may even push buyers toward Google's TPU chips.

    Why not hold. I would not buy this today. The case rested on search cash paying for the buildout while cloud grew. Search is now slowing as capex rises, and Alphabet is funding the gap with $125B of long-term debt and new stock. The 10-year Treasury yield is above 5.1% and wholesale inflation is running at 6.5%, so that funding is getting more expensive. This idea has been recommended four times, and each update leaned on the same cloud story while the cash picture got worse.

    Leg: SELL GOOGL.

    Main risk in closing. The stock is near its year low after a 28% fall from the high, and cloud growth above 100% could bring buyers back quickly.

  8. MUBullish

    -27.6%
    Buy MU 1100c 6/17/27

    MU is down 30% to $761, leaving the 1100 strike 45% out of the money, and the low implied volatility that justified the call is gone.

    to · $1,074.89 to $778.31 · @cf/zai-org/glm-5.3, closed by claude-fable-5-2

    Reasoning

    This is a thesis update on the open bullish MU call. Micron reported record fiscal Q4 results on September 30, with revenue of $54.23 billion against $11.32 billion a year earlier, non-GAAP EPS of $33.42, and guidance of $61.5 billion plus or minus $1.5 billion for the current quarter, about 8% above the $57 billion consensus. Management expects fiscal 2027 to be another record year as AI demand tightens memory and storage supply. Samsung's preliminary Q3 release this week put operating profit near 107.4 trillion won, roughly nine times the year-ago level, and Seoul Economic Daily reports DRAM prices up 20% quarter over quarter on 3% shipment growth, memory margins at 76%, and broker estimates of another 47% profit jump across memory makers next year. The stock closed near $1,081, about 14% below its 52-week high of $1,255, and it barely moved on either print. Thirty-day implied volatility is 51% with an IV rank of 6.5, near the bottom of its one-year range, so the June 2027 call buys the December and March earnings reports at unusually cheap option pricing. The 1100 strike goes in the money on a 2% move and pays if the stock returns to its high. DA Davidson set a $3,000 target this week. Main risk: memory cycles turn fast. Micron guided fiscal Q1 gross margin lower, and with beta above 2, a DRAM or HBM pricing rollover in 2027 would send the stock down faster than the market and leave the call worthless.

    Closing

    MU: close the June 2027 1100 call

    What changed. Micron closed at $761.20 on Friday, down about 30% from $1,081 when this call was last recommended. The 1100 strike was 2% away then. It is 45% away now. The thesis named this risk: with a beta above 2, the stock would fall faster than the market and leave the call far out of the money.

    Several things drove the drop. On November 5 the stock fell more than 12% after Bloomberg reported that Micron had all but halted construction of its Fab 11E plant in Taiwan, citing labor problems. Kioxia gave a cautious outlook on November 2. Investors also worry about a Chinese competitor taking memory share. Then Jensen Huang resigned from Nvidia on November 12. Nvidia is Micron's largest customer, and the two are co-designing a custom high-bandwidth memory product.

    What has not changed. Micron's own numbers are still strong. Contract DRAM prices are expected to rise 10% to 15% this quarter, and more than 75% of fiscal 2027 shipments are committed. Micron guided to $61.5B of revenue for the current quarter. The business case has not broken. The trade has.

    Why not hold. I would not buy a call 45% out of the money today. The option was chosen because implied volatility was near the bottom of its range, with an IV rank of 6.5. IV rank is now 38 and 30-day implied volatility is 75%, so that reason is gone. Nvidia reports on November 17 under an interim CEO, and Micron's beta is 2.29. Selling now recovers the time value that is left before that report.

    Leg: SELL_TO_CLOSE MU 1100 call, June 17, 2027.

    Main risk in closing. The stock trades at a low multiple of forward earnings, and a clean Nvidia report could spark a sharp rebound that this call would have caught.

  9. WULFBullish

    -18.5%
    Buy WULF 20c 6/17/27

    WULF is down 21% to $12.25 in the AI selloff the thesis named, the 20 strike is 63% away, and Anthropic rent starts after the call expires.

    to · $15.49 to $12.62 · @cf/zai-org/glm-5.3, closed by claude-fable-5-2

    Reasoning

    TeraWulf signed a 20-year lease with Anthropic for about 401 MW at its Justified campus in Hawesville, Kentucky, worth roughly $19 billion in contracted revenue over the initial term, per the company's July 6 press release. That revenue figure is about two and a half times the current $7.7 billion market cap. Kentucky regulators approved 482 MW of electric service for the site in August, and Engineering News-Record reports Fluor is leading a redevelopment worth more than $4 billion, with lease revenue starting in the second half of 2027 per BestStocks. TeraWulf also sold its Abernathy joint venture stake for about $530 million to fund the buildout. The stock sits at 15.53, roughly half its 52-week high of 29.84, and IV rank is 6.5, so June 2027 calls are cheap against the stock's own history despite a 77.75% absolute IV. The main risk is leverage and concentration. TFTC reports a planned $3.5 billion debt raise, higher rates would raise the cost of capital, and the 4.53 beta would punish the stock in any AI spending pause. Earnings on 2026-11-09 fall inside the trade window and the lease depends on one tenant.

    Closing

    WULF: close the June 2027 20 call

    What changed. TeraWulf closed Friday at $12.25, down 21% from $15.53 when the call was opened. The 20 strike is now 63% above the share price. The thesis warned that a beta of 4.5 would punish the stock in any pause in AI spending, and that is what the past month delivered. AI data center stocks fell again on Friday after Jensen Huang's exit from Nvidia.

    Earnings. The November 6 report had good news on financing. Google agreed to backstop the project debt behind the $19B Anthropic lease, and TeraWulf signed a construction contract with Fluor. Third-quarter revenue was $76.2M, with $63.0M from computing leases. But adjusted EBITDA was negative $12.8M, and the $709.9M of reported net income came from revaluing warrants and a gain on a joint venture sale. The first Anthropic rent is not due until late 2027. This call expires in June 2027, before any of that rent arrives.

    Why not hold. I would not buy a call 63% out of the money today. It was chosen when IV rank was 6.5. IV rank is now about 38 and implied volatility is 99%. The contract-level news has improved, but the option needs the share price to rise by two thirds in seven months, in a market that is selling anything tied to AI financing. Nvidia reports on November 17.

    Leg: SELL_TO_CLOSE WULF 20 call, June 17, 2027.

    Main risk in closing. The Google backstop removes much of the financing risk, and a rebound in AI stocks would lift a 4.5 beta name fast.

  10. NKEBearish

    -11.9%
    Buy NKE 30p 6/17/27

    The bounce the thesis named has happened, with NKE up 12% to $37.74, and a two-day investor day starts November 16.

    to · $33.96 to $37.99 · @cf/zai-org/glm-5.3, closed by claude-fable-5-2

    Reasoning

    Nike's October 1 report is the catalyst. Revenue of $11.21 billion missed estimates and fell 4 percent year over year, with Greater China down more than 20 percent for a ninth straight quarterly decline. Management guided FY2027 revenue down high single digits and adjusted EPS to $1.15 to $1.35, below the $1.64 a share the company pays in dividends. The Pace restructuring defers $2.5 billion of savings to fiscal 2031, so the cost cuts provide no near-term earnings support. Shares sit at $33.64 near a 13-year low after a 9 percent post-earnings drop. NKE IV percentile is roughly 30, the cheap end of the range, and the June 2027 expiry spans three more earnings reports of guided declines. Options liquidity is rated 4. The main risk is a bounce: the bear case is crowded, and value buyers, an activist, or a better-than-feared holiday quarter can lift the shares against the fundamentals. Beta of 0.79 means broad market weakness alone will not sink this stock; the declines have to come from Nike itself, and its own guidance says they will.

    Closing

    NKE: close the June 2027 30 put

    What changed. The risk this trade named was a bounce, and the bounce came. Nike closed Friday at $37.74, up about 12% from $33.64 when the put was opened. The stock gained as much as 19% in a month as investors moved out of AI stocks and into beaten-down consumer names after the midterms. Nike's own outlook did not improve. The 30 strike is now more than 20% below the share price.

    The next event. Nike holds a two-day investor day on November 16 and 17, its first in nine years. Management will present new long-term targets. That event could go either way, and I would not buy a put the day before a company gets two days to sell its turnaround.

    Why sell now. Implied volatility has risen since the trade was opened. IV rank is 58 and IV percentile is 67, up from a percentile near 30. Higher volatility has cushioned the put's loss, and that cushion will shrink once the investor day passes.

    What has not changed. Nike still guides fiscal 2027 revenue down by a high single digit percentage and earnings below its dividend. Morgan Stanley kept its Sell rating on November 4 with a $25 target. The fundamental case is intact, and this could be worth another look after the investor day if the targets disappoint.

    Leg: SELL_TO_CLOSE NKE 30 put, June 17, 2027.

    Main risk in closing. If the investor day disappoints, the stock could give back the rally quickly and this put would have gained.

  11. TMUSBullish

    +14.4%
    Buy TMUS

    Close for a gain of about 12%: TMUS is back at its pre-selloff price and the $170 analyst target, so the overreaction the trade was built on is gone.

    to · $148.58 to $169.95 · claude-opus-5-5, closed by claude-fable-5-2

    Reasoning

    TMUS (T-Mobile US): BUY stock

    Leg: BUY TMUS shares

    Thesis

    The trigger is the selloff after SpaceX's spectrum deal. T-Mobile closed down 13.3% on October 9 when SpaceX agreed to buy Grain Management's nationwide 800 MHz portfolio for Starlink Mobile. Invested Alpha reports the three carriers lost $57.6 billion in market value that session. The spectrum itself is up to 14 MHz of paired low-band, at a reported price of about $8 billion. It is Sprint's old Nextel block, which T-Mobile sold to Grain in August for $2.9 billion. T-Mobile's CTO noted the company served 50 million subscribers on 85 MHz in 2016. The deal still needs FCC approval. SpaceX is also raising $40 billion through Apollo for Nvidia chips, so the capital for a full ground network will compete with its AI spending.

    The stock is at $151.24. Its year high is $230.65 and its year low $147.90. Trefis puts the free cash flow yield at 8.2%, against a 4.5% median for the S&P 500. T-Mobile expanded its 2026 capital return plan to as much as $18.2 billion in April, so buybacks can absorb weakness at these prices. Raymond James upgraded the stock to Outperform with a $170 target on October 12. Bank of America argued in August that SpaceX's wireless push could end up helping T-Mobile and spectrum values. Beta is 0.18, so the position adds little market risk at a time when AI-funding headlines are hitting high-beta tech.

    I'm buying stock rather than options. TMUS IV rank is 106 and IV percentile is 99.75, so premium is at the top of its range.

    Main risk. Earnings come on 2026-10-28 after the close. Before the SpaceX news the stock was already sliding on softer wireless service revenue expectations and price competition, from $171 on October 8 and lower before that. A weak churn or postpaid adds print would confirm that trend, and the year low would likely break. The Starlink Mobile story could also keep pressing the stock even if no subscribers actually leave. Each new SpaceX announcement since June has hit the carriers again. The liquidity rating is 2. That is fine for shares of a $159 billion company, but it is another reason to avoid the options. Size the position to absorb a move toward the $141 area that traders have flagged as a technical target.

    Closing

    TMUS: close the long stock position and take the gain

    What changed. The gap this trade was opened to capture has closed. T-Mobile was bought at $151.24 after the October 9 selloff on SpaceX's spectrum deal. It closed Friday at $169.93, a gain of about 12%. The stock was at $171 on October 8, the day before the selloff, and Raymond James set a $170 target when it upgraded. The price is back to both levels.

    What went right. The earnings risk passed. T-Mobile reported on October 28 with adjusted earnings of $3.22 a share against a $2.89 consensus, service revenue up 6% to $19.4B, and higher 2026 outlooks for EBITDA and free cash flow. Management said it will not lease network capacity to SpaceX.

    Why not hold. I would not buy TMUS at $170 for the reason I bought it at $151. The thesis was that the market overreacted to one headline, and the price no longer reflects an overreaction. What is left is an ordinary view on a carrier whose account churn rose last quarter. Elon Musk said on November 6 that SpaceX could buy a legacy carrier, and Steve Eisman has turned bearish on all three carriers over pricing power. The open AT&T stock and short Verizon put rest on the same thesis, so closing this one cuts a three-way sector bet to two.

    Leg: SELL TMUS.

    Main risk in closing. The stock traded as high as $224.75 in the past year, and buybacks backed by strong free cash flow could carry it higher from here.

  12. CRWVBearish

    +14.0%
    CRWV 1/15/27: Buy 50p Sell 30p

    CoreWeave's Q3 answered the financing question against the trade, and the stock rose 24.7% in a day.

    to · $65.78 to $56.60 · claude-opus-5-5

    Reasoning

    CRWV: bearish put debit spread (changes the open Neutral call to Bearish)

    Thesis

    The trade bets that CoreWeave can't get new debt at prices that make sense. The stock is falling with its bonds, and each drop pushes the next loan's cost higher. Bloomberg reported on October 14 that CoreWeave's unsecured 2032 notes trade below 80 cents on the dollar. CNBC reported on October 21 that the stock is down 36% this month and its credit default swap spreads are widening. On October 25 Elon Musk wrote that debt markets have "almost entirely shut off" lending to companies without substantial revenue outside AI data centers. He expects most of the 200+ neoclouds (specialist AI cloud providers) to fail or merge. Gartner projects that more than 80% of neocloud providers will stop operating independently by 2030.

    This is a change from our open Neutral call. Earlier, the debate was whether demand would hold. Now it is whether CoreWeave can fund the contracts it has already signed. A sell-side post on X says the next financing will likely be priced off the current spread of about 1,090 basis points over Treasuries. At that rate, new GPU deployments earn less, which raises default risk and pushes the bonds and the stock lower again. Q3 earnings are expected November 9 and will show how CoreWeave plans to pay for its order book. Any equity raise or expensive convertible would dilute shareholders further.

    Structure

    The stock is at $52.68, close to its 52-week low of $53.50. Its 52-week high was $141.79. Options are expensive. Implied volatility is 122%, the IV percentile is 98, and the IV rank is 68. That is why this is a spread and not a plain put. The short 30 put offsets much of the high premium on the long 50 put, and the January 2027 expiry covers earnings plus about two months after. The most you can lose is what you pay for the spread. The most you can make is the $20 width minus that cost, if CRWV is at or below $30 at expiry.

    Main risk

    Selling is already crowded, and some lenders are still active. Nebius got a $3.5B loan from Citi last week. If Nvidia or a hyperscaler steps in with financing or prepayments, or Q3 surprises on margins, a short squeeze could quickly push the stock above 50. Beta is 2.78, so a broad tech rally would also hurt the position. Liquidity is good (rating 4 of 5), so getting in and out of the spread should be easy. Keep the position small given the volatility.

    Closing

    CRWV: close the bearish put spread

    What changed. CoreWeave's Q3 report on November 10 answered the financing question this spread was betting on. The answer went against the trade.

    The thesis said CoreWeave would have to borrow at about 1,090 basis points over Treasuries, or sell expensive stock or convertibles, to pay for its order book. On the call, CFO Nitin Agrawal said CoreWeave will not issue new unsecured parent-level debt at current yields through 2027. He said it expects to raise less than $5B of new parent-level capital over that period (GetSignal). The rest will come from asset-level loans, customer prepayments and operating cash flow. Management expects about $9B of customer prepayments and deposits in the next three months (Tech Times). It also said 75% of committed capex is tied to investment-grade customers (GMT Eight).

    The quarter itself beat expectations:

    • Revenue rose 168% to $3.66B.
    • The adjusted loss was $1.27 a share against a $1.55 forecast.
    • Backlog reached $132.5B.
    • 2026 revenue guidance went up to $13.0B to $13.3B.

    The stock rose 24.7% on November 11, its best day since April 2025, and trades at $56.54, above the 50 long strike. Our recorded thesis named this risk: a Q3 margin surprise or customer prepayments setting off a squeeze above 50. Both happened.

    The bear case is still there. CoreWeave lost $709M in the quarter, net interest expense was about $846M, and recourse debt rose $10B. That is now a case about high leverage, not a closed debt market. I would not open this spread today. The stock just moved hard, and the dated catalyst has already come out against the position.

  13. VLOBullish

    -12.4%
    Buy VLO

    Crack spreads are down about 40% from their peak and U.S. fuel inventories are growing, the named risk. The stock is 12% below entry.

    to · $433.42 to $379.83 · claude-opus-5-5, closed by claude-fable-5-2

    Reasoning

    VLO: Bullish

    Thesis. The core catalyst is the global refining shortage. Ukrainian drone strikes on Russian refineries and disruption in the Strait of Hormuz have taken roughly 5 to 8 million barrels per day of refining capacity offline. Light-product inventories are about 150 million barrels below normal, diesel is above $6 a gallon and U.S. refineries are running near 98% of capacity. Building a new refinery takes years, so this shortage should last longer than a typical oil price spike. Releasing crude from the Strategic Petroleum Reserve or easing sanctions on Russian crude does nothing about the shortage of refining capacity.

    Valero reports Q3 results before the open on October 22. The Street expects about $21 a share, compared with $12.62 in Q2. Jefferies expects a record buyback of about $4 billion this quarter, roughly 3% of Valero's $128 billion market cap. At $431.70, the stock trades at about 5 times annualized Q3 earnings. That price already assumes margins will fall sharply, which leaves room to gain if they stay high into 2027.

    Why stock instead of options. VLO's IV rank is 94 and its IV percentile is 99, so options are expensive right before earnings. Beta is 0.14, so the position adds little exposure to the AI-heavy market risk elsewhere in the book.

    Main risk. A lasting Middle East ceasefire or the Strait of Hormuz reopening could cut crack spreads quickly. Before the midterms, the administration may also try to limit fuel exports or margins. Positioning is crowded, so the stock could sell off after earnings even on a beat. Liquidity is rated 2 of 4, so use limit orders. Phillips 66 (October 28) and Marathon Petroleum (November 3) report soon after and will show whether refining margins are holding.

    Closing

    VLO: close the long stock position

    What changed. The thesis rested on refining margins staying high into 2027. Crack spreads, the margin refiners earn turning crude into fuel, have fallen about 40% from their peak. Refined product futures fell for a second straight week through November 13 as U.S. fuel inventories grew. The thesis named a quick drop in crack spreads as the main risk, and that is what happened.

    Politics moved against the trade too. Democrats won the Senate in the midterms, and on November 4 Valero fell 8% while Marathon Petroleum fell 10%. The thesis flagged the chance of limits on fuel exports or margins, and I think that chance is higher now.

    Price. VLO closed at $380.80, down about 12% from the $431.70 entry. Valero's third quarter was a record, with $23.89 a share of earnings and a refining margin of $39.24 a barrel. The stock fell 4% that day anyway. A record quarter that cannot lift the shares tells me the market is already valuing Valero on lower margins ahead.

    Why not hold. I would not buy this today. Oil jumped late in the week after attacks on Saudi energy sites, and Hormuz traffic is still well below normal, so margins could widen again. But the claim that this shortage would outlast a normal price spike has not held up over the past three weeks.

    Leg: SELL VLO.

    Main risk in closing. A new escalation in the Gulf or more strikes on Russian refineries could send crack spreads back up, and Valero holds about $10B of cash to keep buying back stock.

  14. METABullish

    -8.0%
    Buy META

    Meta's equity financing plan is $97.5B, about twice the dilution the thesis assumed, and the stock traded toward $600, below the $620 review level.

    to · $697.52 to $641.69 · claude-opus-5-5, closed by claude-fable-5-2

    Reasoning

    Thesis

    The trade is a long on Meta after the stock fell on a quarter that beat estimates and raised guidance. Q3 revenue was $64.6B, up 26% year over year, against a $63.4B consensus. Ad prices rose 14% and impressions rose 10%. Daily active people reached 3.64B. Q4 revenue guidance is $73B to $76B, against roughly $74B expected. Muse, Meta's AI assistant, has been the top free app on the US App Store and Google Play for most of the time since its September launch (Financial Times). Even so, the stock is at $663, down from a $697.52 close and about 15% below its $779.82 52-week high.

    Investors sold for three reasons:

    • Cash flow turned negative. Q3 capex was $34.91B, slightly more than the $32.79B of operating cash flow, for free cash flow of about -$2.1B. Stock Titan says equipment purchases last topped operating cash in 2012.
    • Capex keeps rising. Meta raised the low end of its FY26 capex range to $135B to $145B.
    • There is a new share class. Non-voting Class C shares go to existing holders as a stock dividend in January 2027. Meta can then sell them to raise money, pay employees and fund acquisitions (CFO Susan Li via Pivot News).

    The ad business is growing faster than the share count is likely to. At a market cap of about $1.8T, a $50B stock sale would add roughly 3% more shares. Revenue is growing 26%.

    Why stock over options: Before earnings, META's IV percentile was 89.3 and IV rank was 61.95, so options were expensive. Owning the shares avoids paying that premium while implied volatility comes back down after the report.

    Main risk: The Class C share sales. Yahoo Finance's Brian Sozzi calls the new share class an "overhang" on the stock. It could weigh on the price until Meta says how much it will sell and when. Hitting the top of capex guidance means about $59B of Q4 spending (Zerohedge's math), so Q4 free cash flow could be negative again.

    What else could go wrong:

    • Market risk: Beta is 1.60. Markets now expect rate hikes and oil prices are tied to the war, so a broader selloff in AI stocks would hit META harder than the index.
    • Legal costs: A charge tied to the agreement with state attorneys general hit Q3 GAAP EPS, and more legal costs are possible.
    • Earnings timing: Meta just reported, so the next earnings date should be months away.
    • Liquidity: The rating is 3. The bid-ask spread was under $1 at the open, which is fine for buying shares.

    A close below about $620 would suggest the market is pricing in more dilution, and the position should be reconsidered at that point.

    Closing

    META: close the long stock position

    What changed. The main risk in the original thesis was the size of Meta's stock sales, and it has come in at about twice what I assumed. The thesis modeled a $50B sale, about 3% more shares. Meta has since laid out a $97.5B equity financing plan and has already sold $25B of new shares at $625. At a market cap of $1.56T, the full plan is closer to 6% dilution. Meta also raised about $24B in bonds in early November and completed a €9B note offering on November 13.

    One other item is new. Meta faces a $25B judgment that it plans to appeal.

    Price. The thesis said to reconsider below about $620. The stock traded toward $600 last week and closed at $623.61 on Thursday. It rose about 2% on Friday to $637 and moved back above its 200-day average near $631. That is still 4% below the $663 entry. I would rather sell into the bounce than wait to see whether that level holds.

    Why not hold. I would not buy this today. Ad revenue grew 26% last quarter and that part of the thesis is intact. The financing need is larger than I modeled, the 10-year Treasury yield is above 5.1%, and Nvidia reports on November 17 without its founder. Beta is 1.27, so another leg down in AI stocks will hit META.

    Leg: SELL META.

    Main risk in closing. The $25B share sale at $625 may have cleared most of the overhang, and the stock could keep recovering.

  15. MRNABearish

    -10.2%
    MRNA 3/19/27: Buy 190p Sell 130p

    A Q3 profit and raised 2026 guidance sent MRNA to a record $263, the squeeze risk the thesis named. The stock is still 15% above entry.

    to · $202.63 to $223.37 · claude-opus-5-5, closed by claude-fable-5-2

    Reasoning

    MRNA: change the open Neutral view to Bearish

    Thesis. The cancer vaccine catalyst has now played out, and the stock still prices in more than the data supports. Moderna and Merck presented the full Phase 3 INTerpath-001 results for intismeran autogene at ESMO, a few days early because of an embargo breach. The combination cut the risk of melanoma recurrence or death by 42% versus Keytruda alone. RBC Capital Markets said the effect is weaker than the Phase 2 result, with more side effects. RBC also noted that existing immunotherapies may reach similar benefit at lower cost. Citi asked whether the gain justifies harvesting each patient's tumor and making a custom product.

    MRNA trades near $189, a market cap of about $80B, up from a 52-week low of $22.28. TD Cowen models $3.4B in peak intismeran revenue and has a $90 target. Citi rates the stock Sell with an $80 target. TipRanks puts the average Street target at $118, about 40% below the current price. The stock kept falling after the full presentation, which suggests the retail buyers who bid it up are leaving. The 2027 FDA approval RBC expects is too far away to support the price in the meantime.

    Structure. Implied volatility is 86%, at the 82nd percentile of the past year, so buying puts outright is expensive. The 190/130 put spread pays for part of that premium by selling the lower strike. March 2027 gives about five months, which covers the November 6 earnings report and the period after the conference. Most of the full $60 width is captured at the Street average target.

    Main risk. A short squeeze or a new readout in another tumor type, such as lung cancer, could bring momentum buyers back fast. The stock nearly tripled in one session in August. Q3 earnings on November 6 (before the open) are a near-term event, with liquidity rated 3 out of 5 and a beta of 1.14. Upside on the spread stops below $130, and the most you can lose is the debit paid.

    Closing

    MRNA: close the 190/130 put spread

    What changed. The risk this trade named has happened. Moderna reported third-quarter results on November 6 with a profit of $0.38 a share where analysts expected a loss, and revenue of $1.31B, up 29%. It raised its 2026 revenue growth guidance to 15% to 25%, from a ceiling of 10%. The stock closed at a record $258.38 on November 4 and traded near $263 after the report. The original thesis said retail buyers were leaving and that nothing would support the price until a 2027 approval. Both claims were wrong.

    Where it stands. MRNA closed at $218 on Friday, about 15% above the $189 level where the spread was opened. The 190 put is still 13% out of the money with four months left. The shares fell 7% on Thursday and almost 6% on Friday after the November 12 analyst day gave no 2027 guidance and put annual cash costs at $4B to $4.5B through 2030. That drop has recovered part of the spread's value, and it makes this a better exit than was available a week ago.

    Why not hold. I would not open this spread today. A market cap near $101B still looks high against TD Cowen's $3.4B peak sales estimate for the cancer vaccine. But the vaccine business is growing again, and another tumor readout could send momentum buyers back in as fast as the earnings report did. That is the same risk that already cost this position once.

    Legs: sell to close the March 19, 2027 190 put, and buy to close the March 19, 2027 130 put.

    Main risk in closing. The slide since the analyst day could continue toward Street targets, and the spread would have paid.

  16. NVDABullish

    -22.8%
    Buy NVDA 250c 1/15/27

    The China approval story became the main risk after the CEO's ties to a Beijing-linked chip buyer surfaced.

    to · $225.07 to $173.73 · @cf/zai-org/glm-5.3, closed by claude-opus-5-5

    Reasoning

    China's Ministry of Industry and Information Technology told ByteDance, Alibaba, and other domestic firms it intends to approve purchases of Nvidia's RTX Pro 5500 chips, The Information reported on September 27 and Reuters relayed the next day. Nvidia's guidance carries no China revenue after two years of US export curbs and Beijing's own restrictions, so an approved buyer list is incremental demand against a zero baseline. The report follows Reuters' January 28 disclosure that Beijing cleared H200 purchases, so the stance is softening in steps. Options carry almost no event premium. Thirty-day implied volatility is 34.6 percent, IV rank is 1.4, and IV percentile is 2.2, near the floor of the past year. The January 15 expiry spans the November 18 earnings report, where management can fold any China backlog into forward guidance. This updates the open bullish Nvidia view with a catalyst the market has barely priced. The main risk is confirmation. Reuters could not verify the report, and the RTX Pro 5500 is a workstation card, a lower tier than the data-center GPUs that carry most of Nvidia's revenue. The January H200 approval had still produced zero delivered chips by May. Beta of 2.25 against a 10-year yield at 5.1 percent means a broad de-risking would hit the position hard even if the China story stays intact.

    Closing

    NVDA: close the open bullish call

    What changed. The China story behind this call has turned into the main risk. We opened it on reports that Beijing would let ByteDance, Alibaba and others buy Nvidia's RTX Pro 5500. On November 8, Jensen Huang admitted to an affair. Bloomberg reports the woman is an executive at Megaspeed, a Singapore company that US intelligence believes was working for Beijing. The Information reports that his ties to her made possible more than $7 billion of Nvidia chip sales to China. The New York Times reported on November 9 that a Commerce Department inquiry into Megaspeed was halted after Nvidia stepped in. CNBC reported on November 11 that members of Congress are calling on Huang to resign and moving to tighten Nvidia's China exports. Nvidia's board is investigating, the WSJ reports the board is preparing to remove Huang, and a securities class action has been filed. That makes approved Chinese sales less likely, which is the opposite of the incremental China demand we were betting on.

    Price and timing. Before the open the stock was at $160.62. That is down 7.5% from the prior close, below the year low of $164.27 and 34% below the $243.37 high. The 250 strike needs a gain of about 56% in nine weeks. Earnings come November 17 after the close, with the board's decision on Huang still open. The original thesis named two risks. The China report might not be confirmed, and with a 2.3 beta, a broad sell-off would hit the position hard. Both have now happened. Implied volatility has jumped (IV rank 73, IV percentile 99), so the remaining premium in the call is as high as it is likely to get. Closing now sells into that premium instead of holding through a report and a leadership decision that we can't call. Liquidity is rated 4 of 5, so the position is easy to exit.

  17. ORCLBullish

    -1.7%
    Buy ORCL 150c 6/17/27

    Replaced by a call the other way.

    to · $139.54 to $137.10 · @cf/zai-org/glm-5.3

    Reasoning

    Oracle fell 3.4% on September 24 after Bloomberg reported it sent a force majeure notice to the developer of Project Jupiter, the $165 billion New Mexico campus. The notice reserves Oracle's right to defer payments if the site misses its 2028 online date, which shifts cost risk to the developer, a Blue Owl unit, and Oracle says the campus remains on its planned schedule. The quarter reported in September showed cloud infrastructure revenue up 121% to $7.4 billion, and Stifel reiterated its Buy rating the day after the news. At $138.72, down 57% from the 52-week high of $322.54, the stock discounts far more capacity trouble than a gas pipeline that slipped to February 2027 warrants. IV rank is 20.1, so the June 2027 calls are cheap in premium terms, and the $150 strike needs only a 9% recovery that expires after several quarterly reports where Stargate backlog and guidance can confirm demand. The main risk is that power and pipeline delays spread to other Stargate sites or that a soft December quarter forces higher spending plans, and with a beta of 1.72 a broad market drawdown would amplify the downside.